Skip to main content
. 2021 Oct 25;38(12):5721–5736. doi: 10.1007/s12325-021-01947-9

Fig. 2.

Fig. 2

Hyponatremia symptoms occurring in ≥1% of patients at either baseline or at any time during tolvaptan treatment. Baseline includes any symptoms starting in the 31 days up to tolvaptan initiation. Percentages are shown for the total number of patients (N = 252)